Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 2Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Neoplasm Metastasis 14Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 8Ovarian Neoplasms 6Colorectal Neoplasms 6Uveal Melanoma 5Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Mesothelioma 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma, Transitional Cell 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Lung Neoplasms 4Carcinoma, Merkel Cell 4Advanced Cancer 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Liver Neoplasms 3Hodgkin Disease 3Head and Neck Neoplasms 3Carcinoma 3

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Ipilimumab × Clear all
NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

ModernaTX, Inc.

Phase 1/2 Recruiting
361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03233152 2025-11-21

GlitIpNi

Universitair Ziekenhuis Brussel

Phase 1/2 Active not recruiting
110 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡